334 related articles for article (PubMed ID: 23141494)
1. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
2. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
3. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
4. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
5. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
Miller AB; Piña IL
Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
[TBL] [Abstract][Full Text] [Related]
6. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
[TBL] [Abstract][Full Text] [Related]
9. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Kao DP; Lewsey JD; Anand IS; Massie BM; Zile MR; Carson PE; McKelvie RS; Komajda M; McMurray JJ; Lindenfeld J
Eur J Heart Fail; 2015 Sep; 17(9):925-35. PubMed ID: 26250359
[TBL] [Abstract][Full Text] [Related]
10. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
[TBL] [Abstract][Full Text] [Related]
11. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
Clin Res Cardiol; 2021 Aug; 110(8):1234-1248. PubMed ID: 33301080
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
14. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
Zile MR; Gottdiener JS; Hetzel SJ; McMurray JJ; Komajda M; McKelvie R; Baicu CF; Massie BM; Carson PE;
Circulation; 2011 Dec; 124(23):2491-501. PubMed ID: 22064591
[TBL] [Abstract][Full Text] [Related]
20. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
